GlaxoSmithKline Pharmaceuticals
- P/E
- 40.16
Key Fundamentals
MidcapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 61.40%
- Debt to Equity
- 0.01
- EPS (TTM)
- ₹63.05
- Book Value
- ₹133.85
- Market Cap
- —
- P/E (TTM)
- 40.16
- P/B
- 18.92
- ROE
- 45.60%
- Dividend Yield
- 2.21%
- EBITDA
- ₹1,455 Cr
- 52W High
- ₹3,120.70
- 52W Low
- ₹2,088.10
- Day Range
- ₹2,495.00 – ₹2,625.50
- Volume
- 2,12,237
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| GlaxoSmithKline Pharmaceuticals (this company) | ₹2,531.80 | 40.16 | ₹43,404 Cr | 18.92 | 2.21% | 45.60% | 61.40% | ₹3,955 Cr | ₹1,068 Cr |
| Median 8 companies | ₹2,048.60 | 39.49 | ₹1,25,337 Cr | 7.29 | 0.70% | 17.40% | 19.15% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 78
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 59
- Good
- Cheap vs sector & own history 24% weight
- Growth
- 14
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 84
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 19
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 54
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
3- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
- Company has been maintaining a healthy dividend payout of 94.6%
Weaknesses
2- Stock is trading at 19.0 times its book value
- The company has delivered a poor sales growth of 5.49% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 8 | 6 | 5 |
| Oscillators | Bearish | 2 | 6 | 1 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |
Oscillators
Bearish
Overall
Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 44.50
- Neutral
- MACD (12,26,9)
- −54.36
- Bullish
- SMA (50)
- 2,739.82
- Bearish
- SMA (200)
- 2,515.61
- Bullish
As of
Analyst Rating
3 of 4 analysts rate Buy, 1 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +3.02% |
|---|---|
| 5Y | +5.49% |
| 3Y | +5.53% |
| 1Y | +1.95% |
| TTM | +5.75% |
Net profit
| 10Y | +10.67% |
|---|---|
| 5Y | +23.68% |
| 3Y | +19.24% |
| 1Y | +11.64% |
| TTM | +12.42% |
Operating cash flow
| 10Y | +20.58% |
|---|---|
| 5Y | +9.33% |
| 3Y | +23.11% |
| 1Y | −30.00% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +17.41 pp |
|---|---|
| 5Y | +13.81 pp |
| 3Y | +9.53 pp |
| 1Y | +2.80 pp |
| TTM | +2.20 pp |
Revenue by year
| Mar 2017 | ₹2,908 Cr |
|---|---|
| Mar 2018 | ₹2,871 Cr |
| Mar 2019 | ₹3,128 Cr |
| Mar 2020 | ₹3,224 Cr |
| Mar 2021 | ₹2,926 Cr |
| Mar 2022 | ₹3,278 Cr |
| Mar 2023 | ₹3,252 Cr |
| Mar 2024 | ₹3,454 Cr |
| Mar 2025 | ₹3,749 Cr |
| Mar 2026 | ₹3,822 Cr |
Net profit by year
| Mar 2017 | ₹337 Cr |
|---|---|
| Mar 2018 | ₹351 Cr |
| Mar 2019 | ₹445 Cr |
| Mar 2020 | ₹93.00 Cr |
| Mar 2021 | ₹358 Cr |
| Mar 2022 | ₹1,695 Cr |
| Mar 2023 | ₹611 Cr |
| Mar 2024 | ₹590 Cr |
| Mar 2025 | ₹928 Cr |
| Mar 2026 | ₹1,036 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
As of 2026-10-30, Glaxosmithkline Pharmaceuticals Ltd trades at ₹2,494.3 with a market cap of ₹42,255 Cr, commanding a PE of 39.56x and a price-to-book of 18.64x. The company operates with virtually no debt (debt-to-equity of 0.01) and delivers a ROE of 45.69%, though revenue growth has remained modest at a 5% CAGR over five years.
- Virtually debt-free balance sheet with a debt-to-equity ratio of just 0.01, providing significant financial resilience and flexibility
- Exceptional return on equity of 45.69% and ROCE of 55.36% as of 2026-10-30, indicating highly efficient capital deployment relative to pharma peers
- Consistent ROE track record with 3-year average ROE of 43% and 5-year average of 48%, demonstrating sustained profitability
- Healthy dividend yield of 2.27% backed by a payout ratio of 94.6%, making it one of the more generous dividend payers in Indian pharma
- Compounded profit growth of 18% over 3 years and 15% over 5 years, outpacing sales growth and reflecting improving margins or operating leverage
- TTM sales growth of 6% shows a slight acceleration compared to the 5-year compounded sales CAGR of 5%, suggesting some momentum in the top line
- Stock is trading roughly 20% below its 52-week high of ₹3,120.7, which may reflect a more accessible entry zone compared to recent peaks
- Price-to-book ratio of 18.64x is exceptionally high, pricing in substantial future earnings growth that the top line has not yet demonstrated
- Compounded sales growth of just 3% over 10 years and 5% over 5 years points to a structurally slow-growing revenue base
- Stock CAGR of -8% over the last 1 year indicates recent negative price momentum and potential investor re-rating of the stock
- The 94.6% dividend payout ratio, while attractive for income, leaves very little retained earnings for reinvestment and organic growth initiatives
- TTM profit growth of 11% has decelerated from the 3-year compounded rate of 18%, suggesting earnings momentum may be tapering
- 10-year compounded sales growth of just 3% versus 10-year profit growth of 10% raises questions about how long margin expansion can compensate for sluggish revenue
- Stock trades about 19% above its 52-week low of ₹2,088.1, having recovered from lows without a clear catalyst in top-line acceleration
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Limited news flow for GSK Pharma this period with only a routine trading window closure ahead of Q2FY27 results. No material headwinds or positive catalysts have emerged. Investors should watch for the upcoming quarterly results for directional cues on earnings and growth trajectory.
- Trading window closes Oct 1 Sep 25
GSK Pharma closes its trading window from October 1, 2026 ahead of Q2FY27 results. The window remains shut until 48 hours after the financial results announcement.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 762 | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 | 1,184 |
| Expenses | 618 | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 | 644 | 643 | 782 |
| Operating Profit | 144 | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 | 371 | 351 | 296 | 402 |
| OPM % | 19% | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% | 36% | 35% | 31% | 34% |
| Other Income | 54 | 28 | −135 | 32 | 36 | 39 | 35 | 41 | 44 | 36 | 50 | 36 | 44 | 73 |
| Interest | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 |
| Depreciation | 16 | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 | 16 | 15 |
| PBT | 181 | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 | 373 | 322 | 459 |
| Tax % | 27% | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 26% | 26% | 26% | 27% |
| Net Profit | 132 | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 | 296 | 278 | 237 | 336 |
| EPS (₹) | 7.81 | 12.84 | 2.7 | 11.48 | 10.76 | 14.91 | 13.57 | 15.52 | 12.1 | 15.2 | 17.45 | 16.4 | 14 | — |
Sep 2026: from the results filed on 3 Nov 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2015 15m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,305 | 2,838 | 2,908 | 2,871 | 3,128 | 3,224 | 2,926 | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 | 3,955 |
| Expenses | 2,672 | 2,360 | 2,489 | 2,363 | 2,527 | 2,567 | 2,327 | 2,516 | 2,447 | 2,545 | 2,570 | 2,512 | 2,601 |
| Operating Profit | 633 | 478 | 420 | 508 | 601 | 657 | 598 | 762 | 804 | 909 | 1,179 | 1,309 | 1,354 |
| OPM % | 19% | 17% | 14% | 18% | 19% | 20% | 20% | 23% | 25% | 26% | 31% | 34% | 34% |
| Other Income | 149 | 125 | 119 | 70 | 131 | −262 | 9 | 1,401 | 103 | −21 | 149 | 166 | 166 |
| Interest | 0 | 0 | 0 | 0 | 1 | 6 | 4 | 2 | 2 | 2 | 1 | 3 | 3 |
| Depreciation | 25 | 25 | 27 | 38 | 49 | 83 | 79 | 68 | 66 | 70 | 67 | 66 | 67 |
| PBT | 756 | 578 | 511 | 540 | 683 | 306 | 525 | 2,093 | 839 | 816 | 1,260 | 1,406 | 1,449 |
| Tax % | 37% | 35% | 34% | 35% | 35% | 70% | 32% | 19% | 27% | 28% | 26% | 26% | — |
| Net Profit | 476 | 376 | 337 | 351 | 445 | 93 | 358 | 1,695 | 611 | 590 | 928 | 1,036 | 1,068 |
| EPS (₹) | 28.12 | 22.2 | 19.88 | 20.7 | 26.29 | 5.5 | 21.14 | 100 | 36.05 | 34.83 | 54.75 | 61.15 | 63.05 |
| Div. Payout % | 111% | 113% | 75% | 85% | 76% | 727% | 142% | 90% | 89% | 92% | 99% | 93% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 169 | 169 | 169 | 169 | 169 | 169 | 169 | 169 |
| Reserves | 1,744 | 2,099 | 1,922 | 1,973 | 1,970 | 1,651 | 1,309 | 2,494 | 1,572 | 1,608 | 1,782 | 2,098 |
| Borrowings | 3 | 2 | 2 | 1 | 1 | 0 | 35 | 20 | 16 | 19 | 10 | 33 |
| Other Liabilities | 1,384 | 869 | 995 | 1,889 | 1,771 | 1,315 | 1,602 | 1,950 | 1,570 | 1,760 | 2,147 | 2,023 |
| Total Liabilities | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 |
| Fixed Assets | 123 | 204 | 258 | 325 | 432 | 758 | 387 | 331 | 330 | 321 | 284 | 281 |
| CWIP | 115 | 268 | 605 | 923 | 1,003 | 120 | 13 | 30 | 20 | 14 | 14 | 33 |
| Investments | 0 | 6 | 0 | 0 | 0 | 0 | 0 | 366 | 518 | 813 | 1,118 | 1,392 |
| Other Assets | 2,977 | 2,577 | 2,140 | 2,700 | 2,477 | 2,257 | 2,715 | 3,907 | 2,458 | 2,408 | 2,692 | 2,618 |
| Total Assets | 3,216 | 3,055 | 3,004 | 3,947 | 3,911 | 3,136 | 3,115 | 4,633 | 3,327 | 3,557 | 4,108 | 4,324 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 338 | 139 | 234 | 473 | 409 | 490 | 578 | 811 | 484 | 582 | 1,290 | 903 |
| Investing | 180 | 499 | 301 | −104 | −153 | −57 | 418 | −406 | 808 | 9 | −46 | 397 |
| Financing | −497 | −638 | −511 | −307 | −358 | −428 | −696 | −524 | −1,543 | −562 | −769 | −737 |
| Net Cash Flow | 21 | 0 | 24 | 62 | −102 | 6 | 300 | −119 | −251 | 29 | 475 | 563 |
| Free Cash Flow | 175 | −69 | −24 | 639 | 166 | 336 | 536 | 2,371 | 451 | 573 | 1,273 | 870 |
| CFO/OP | 93 | 72 | 94 | 133 | 101 | 103 | 121 | 122 | 93 | 92 | 116 | 93 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 11 | 16 | 21 | 19 | 14 | 11 | 27 | 23 | 22 | 23 | 28 | 26 |
| Inventory Days | 91 | 156 | 111 | 147 | 131 | 135 | 159 | 144 | 131 | 144 | 126 | 124 |
| Days Payable | 74 | 97 | 73 | 149 | 109 | 100 | 135 | 156 | 122 | 171 | 186 | 154 |
| Cash Conversion Cycle | 27 | 75 | 60 | 17 | 36 | 46 | 50 | 11 | 31 | −4 | −31 | −4 |
| Working Capital Days | −48 | 26 | 7 | −90 | −72 | −38 | −39 | −94 | −57 | −64 | −99 | −91 |
| ROCE % | 42% | 29% | 22% | 26% | 31% | 33% | 38% | 37% | 36% | 51% | 63% | 61% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view GlaxoSmithKline Pharmaceuticals insights
66 extracted metrics across FY14–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT
- Q4 FY26 concall · Jun 2026Transcript PPT
- Q4 FY26 concall · May 2026PPT
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025PPT
- 3 Aug 2026
- 13 May 2026
- 6 Nov 2025
- General announcements 3 Nov 2026
- General announcements 3 Nov 2026
- General announcements 28 Oct 2026
Frequently Asked Questions about GlaxoSmithKline Pharmaceuticals
What does Glaxosmithkline Pharmaceuticals Ltd do?
Where is Glaxosmithkline Pharmaceuticals Ltd (GLAXO) listed?
Which sector does Glaxosmithkline Pharmaceuticals Ltd belong to?
What is the PE ratio of Glaxosmithkline Pharmaceuticals Ltd?
What is the 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd?
Does Glaxosmithkline Pharmaceuticals Ltd pay dividends?
What is the Return on Equity (ROE) of Glaxosmithkline Pharmaceuticals Ltd?
Company Information
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/GLAXO.md for Glaxosmithkline Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.